Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.

Conceição, IsabelIsabelConceiçãoBerk, John LJohn LBerkWeiler, MarkusMarkusWeilerKowacs, Pedro APedro AKowacsDasgupta, Noel RNoel RDasguptaKhella, SamiSamiKhellaCHI-CHAO CHAOAttarian, ShahramShahramAttarianKwoh, T JesseT JesseKwohJung, Shiangtung WShiangtung WJungChen, JerseyJerseyChenViney, Nicholas JNicholas JVineyYu, Rosie ZRosie ZYuGertz, MorieMorieGertzMasri, AhmadAhmadMasriCruz, Márcia WaddingtonMárcia WaddingtonCruzCoelho, TeresaTeresaCoelho2026-03-162026-03-162024-10https://scholars.lib.ntu.edu.tw/handle/123456789/736392enAmyloidosisAntisense oligonucleotideTransthyretinTreatment efficacyTreatment safetySwitching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.journal article10.1007/s00415-024-12616-639138650